Botulinum toxin therapy of dystonia

被引:27
作者
Dressler, Dirk [1 ]
Saberi, Fereshte Adib [1 ]
Rosales, Raymond L. [2 ]
机构
[1] Hannover Med Sch, Dept Neurol, Movement Disorders Sect, Carl Neuberg Str 1, D-30625 Hannover, Germany
[2] Univ Santo Tomas Hosp, Neurosci Inst, Dept Neurol & Psychiat, Manila, Philippines
关键词
Botulinum toxin; Therapy; Dystonia; Treatment strategies; CERVICAL DYSTONIA; BLEPHAROSPASM; STRATEGIES; SAFETY;
D O I
10.1007/s00702-020-02266-z
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Botulinum toxin (BT) is used to treat a large number of muscle hyperactivity syndromes. Its use in dystonia, however, is still one of the most important indications for BT therapy. When BT is injected into dystonic muscles, it produces a peripheral paresis which is localised, well controllable and follows a distinct and predictable time course of around 3 months. Adverse effects are always transient and usually mild, long-term application is safe. With this profile BT can be used to treat cranial dystonia, cervical dystonia and limb dystonia including writer's and musician's cramps. The recent introduction of BT high dose therapy also allows to treat more wide-spread dystonia including segmental and generalised dystonia. BT can easily be combined with other anti-dystonic treatments such as deep brain stimulation and intrathecal baclofen application. Best treatment results are obtained when BT therapy is integrated in the multimodal and long-term 'multilayer concept of treatment of dystonia'. The biggest challenge for the future will be to deliver state of the art BT therapy to all dystonia patients in need, regardless of whether they live in developed countries or beyond.
引用
收藏
页码:531 / 537
页数:7
相关论文
共 32 条
  • [1] Posterior auricular muscle 'dystonia'
    Alonso-Navarro, H.
    Puertas, I.
    Cabrera-Valdivia, F.
    de Toledo-Heras, M.
    Garcia-Albea, E.
    Jimenez-Jimenez, F. J.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 (07) : E14 - E15
  • [2] CLINICAL AND ELECTROMYOGRAPHIC FEATURES OF LEVATOR PALPEBRAE-SUPERIORIS MUSCLE DYSFUNCTION IN INVOLUNTARY EYELID CLOSURE
    ARAMIDEH, M
    DEVISSER, BWO
    KOELMAN, JHTM
    BOUR, LJ
    DEVRIESE, PP
    SPEELMAN, JD
    [J]. MOVEMENT DISORDERS, 1994, 9 (04) : 395 - 402
  • [3] Barth K, 1993, KRANKENGYMNASTIK, V45, P134
  • [4] Sonography-guided injection of botulinum toxin A in children with cerebral palsy
    Berweck, S
    Feldkamp, A
    Francke, A
    Nehles, J
    Schwerin, A
    Heinen, F
    [J]. NEUROPEDIATRICS, 2002, 33 (04) : 221 - 223
  • [5] Costa J, 2005, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004899.PUB2
  • [6] Botulinum toxin therapy of writer's cramp
    Das, CP
    Dressler, D
    Hallett, M
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 55 - 59
  • [7] Five-year experience with incobotulinumtoxinA (Xeomin®): the first botulinum toxin drug free of complexing proteins
    Dressler, D.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 (03) : 385 - 389
  • [8] Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis
    Dressler, D
    Benecke, R
    [J]. EUROPEAN NEUROLOGY, 2003, 49 (01) : 34 - 38
  • [9] Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therapy
    Dressler, D
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2000, 7 (06) : 713 - 718
  • [10] Antibody-induced failure of botulinum toxin type B therapy in de novo patients
    Dressler, D
    Bigalke, H
    [J]. EUROPEAN NEUROLOGY, 2004, 52 (03) : 132 - 135